Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.67 |
| ▸ | PLK1 | P53350 | 1/20 | 0.53 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 5/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CTSD | P07339 | 1/20 | 0.45 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.45 |
| ▸ | PYGL | P06737 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL655826 | 0.86 | ALDH1A1 (0.53) | ALDH1A1PLK1GAAMAPTHTT | |
| SCHEMBL5679153 | 0.86 | ALDH1A1 (0.67) | ALDH1A1CRBNGAAMAPTHTT | |
| SCHEMBL728203 | 0.86 | ALDH1A1 (0.67) | ALDH1A1CRBNGAAMAPTHTT | |
| Hydrochloric Acid SCHEMBL2553196 | 0.85 | ALDH1A1 (0.51) | ALDH1A1PLK1GAAMAPTHTT | |
| SCHEMBL5925494 | 0.83 | GAA (0.64) | ALDH1A1CRBNGAAMAPTSMN1; SMN2 | |
| SCHEMBL224165 | 0.82 | ALDH1A1 (0.71) | ALDH1A1CRBNGAAMAPTHTT | |
| SCHEMBL3850604 | 0.82 | ALDH1A1 (0.61) | ALDH1A1CRBNMAPTMAPK1SMN1; SMN2 | |
| SCHEMBL29530877 | 0.82 | ALDH1A1 (0.61) | ALDH1A1CRBNMAPTMAPK1SMN1; SMN2 | |
| SCHEMBL3110944 | 0.82 | ALDH1A1 (0.61) | ALDH1A1CRBNGAAMAPTHTT | |
| SCHEMBL3850748 | 0.82 | MAPT (0.63) | ALDH1A1CRBNGAAMAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4640678-A1 | NOVEL OXO-PYRIDINE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | Chengdu Shibeikang Biomedical Technology Co., Ltd. (CN) | 2025-10-29 | — | — | EP | disclosed |
| CN-116082303-B | Novel oxopyridines, intermediates and uses thereof | 成都施贝康生物医药科技有限公司 | 2025-02-25 | — | — | CN | disclosed |
| WO-2024131841-A1 | NOVEL OXO-PYRIDINE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | 成都施贝康生物医药科技有限公司 | 2024-06-27 | — | — | WO | disclosed |
| CN-116082303-A | Novel oxopyridines, intermediates and uses thereof | 成都施贝康生物医药科技有限公司 | 2023-05-09 | — | — | CN | disclosed |
| US-20230091047-A1 | FUSED RING PYRIMIDONE DERIVATIVES FOR USE IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | JANSSEN PHARMACEUTICA NV (BE) | 2023-03-23 | — | — | US | disclosed |
| US-9913817-B2 | Methods for preventing or reducing colon carcinogenesis | NOGRA PHARMA LIMITED (IE) | 2018-03-13 | — | — | US | disclosed |
| US-20180064667-A1 | METHODS OF TREATING LACTOSE INTOLERANCE | NOGRA PHARMA LTD (IE) | 2018-03-08 | — | — | US | disclosed |
| US-20170056349-A1 | Methods for Preventing or Reducing Colon Carcinogenesis | NOGRA PHARMA LIMITED (IE) | 2017-03-02 | — | — | US | disclosed |
| US-9487491-B2 | Diamino heterocyclic carboxamide compound | ASTELLAS PHARMA INC. (JP) | 2016-11-08 | — | — | US | disclosed |
| EP-3009428-A1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | Astellas Pharma Inc. (JP) | 2016-04-20 | — | — | EP | disclosed |
| US-20140371196-A1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2014-12-18 | — | — | US | disclosed |
| US-8501806-B2 | Methods for preventing or reducing colon carcinogenesis | NOGRA PHARMA LIMITED (IE) | 2013-08-06 | — | — | US | disclosed |
| US-8138357-B2 | Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field | GIULIANI INTERNATIONAL LIMITED (IE) | 2012-03-20 | — | — | US | disclosed |
| EP-2428508-A1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | Astellas Pharma Inc. (JP) | 2012-03-14 | — | — | EP | disclosed |
| US-20120040968-A1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | WATERS TECHNOLOGIES CORPORATION (US) | 2012-02-16 | — | — | US | disclosed |
| US-20110288058-A1 | Methods for Preventing or Reducing Colon Carcinogenesis | NOGRA PHARMA LIMITED (IE) | 2011-11-24 | — | — | US | disclosed |
| US-20110288177-A1 | Methods for Preventing or Reducing Colon Carcinogenesis | NOGRA PHARMA LIMITED (IE) | 2011-11-24 | — | — | US | disclosed |
| US-20110152225-A1 | PPAR-Gamma Agonists for the Induction of Cationic Antimicrobial Peptide Expression as Immunoprotective Stimulants | NOGRA PHARMA LIMITED (IE) | 2011-06-23 | — | — | US | disclosed |
| WO-2010128659-A1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | アステラス製薬株式会社 (JP) | 2010-11-11 | — | — | WO | disclosed |
| US-20090118357-A1 | Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field | GIULIANI INTERNATIONAL LIMITED (IE) | 2009-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170056349-A1 | Methods for Preventing or Reducing Colon Carcinogenesis | NQO1, NFE2L2, CYBB | ALDH1A1 103/4885PLK1 4308/4885CRBN 1306/4885 |
| US-20230091047-A1 | FUSED RING PYRIMIDONE DERIVATIVES FOR USE IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | HAVCR2, HCCS, TYMP | ALDH1A1 1508/4885PLK1 430/4885CRBN 4193/4885 |
| US-20090118357-A1 | Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field | EGFR, ERBB3, FGFR3 | ALDH1A1 2287/4885PLK1 3830/4885CRBN 704/4885 |
| US-20140371196-A1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | EML4, ALK, ERBB4 | ALDH1A1 1554/4885PLK1 1966/4885CRBN 1454/4885 |
| US-20110288058-A1 | Methods for Preventing or Reducing Colon Carcinogenesis | NQO1, NFE2L2, CYBB | ALDH1A1 103/4885PLK1 4308/4885CRBN 1306/4885 |
| US-20110288177-A1 | Methods for Preventing or Reducing Colon Carcinogenesis | APC, GSTK1, GSTA1 | ALDH1A1 126/4885PLK1 3854/4885CRBN 688/4885 |
| US-20120040968-A1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | EML4, ALK, ERBB4 | ALDH1A1 1554/4885PLK1 1966/4885CRBN 1454/4885 |
| US-20180064667-A1 | METHODS OF TREATING LACTOSE INTOLERANCE | LCT, LPL, PPARG | ALDH1A1 530/4885PLK1 3550/4885CRBN 4274/4885 |
| US-20110152225-A1 | PPAR-Gamma Agonists for the Induction of Cationic Antimicrobial Peptide Expression as Immunoprotective Stimulants | PPARG, FABP2, PPARD | ALDH1A1 983/4885PLK1 4399/4885CRBN 4784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.